Details for Patent: 8,143,212

Which drugs does patent 8,143,212 protect, and when does it expire?

Patent 8,143,212 protects DALVANCE and is included in one NDA.

This patent has fifty-eight patent family members in twenty countries.

Summary for Patent: 8,143,212

Title:	Dalbavancin compositions for treatment of bacterial infections
Abstract:	The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A.sub.0, A.sub.1, B.sub.1, B.sub.2, C.sub.0, C.sub.1, isoB.sub.0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Colombo; Luigi (Malnate, IT), Ciabatti; Romeo (Novate Milanese, IT)
Assignee:	Vicuron Pharmaceuticals Inc. (Morristown, NJ)
Application Number:	12/476,785
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,143,212

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883-001	May 23, 2014		RX	Yes	Yes						TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

International Family Members for US Patent 8,143,212

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003294262
Australia	2003298662
Australia	2003299561
Australia	2005325261
Australia	2011200423
Brazil	PI0510269